To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Effect of tranexamic acid and indirect factor Xa inhibitor on blood loss and DVT after TKA

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
February 2014

Effect of tranexamic acid and indirect factor Xa inhibitor on blood loss and DVT after TKA

Vol: 3| Issue: 2| Number:49| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Less blood loss under concomitant administration of tranexamic acid and indirect factor Xa inhibitor following total knee arthroplasty: a prospective randomized controlled trial

Knee Surg Sports Traumatol Arthrosc. 2013 Nov;21(11):2611-7

Contributing Authors:
SH Lee KY Cho S Khurana KI Kim

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

72 patients scheduled to receive primary unilateral cemented total knee arthroplasty (TKA) were randomly assigned into one of two groups to determine if the simultaneous application of tranexamic acid and indirect factor Xa inhibitor was a safe and effective blood loss prevention treatment when compared to indirect factor Xa inhibitor alone. Patients either received tranexamic acid in combination ...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue